Biasca, Switzerland, March 23, 2023 – HAS Healthcare Advanced Synthesis, one of the leading development and manufacturing companies in the international chemical-pharmaceutical industry, delivering for years active pharmaceutical ingredients (APIs), high-activity active pharmaceutical ingredients (HPAPIs) and anticancer compounds for pharmaceutical and biotechnology companies, today announces that it has achieved carbon neutrality for the year 2021. This allows HAS Healthcare Advanced Synthesis to establish itself as a leader among Ticino companies in terms of its climate policy. This result, which confirms the company’s commitment to combating climate change and mitigating environmental impacts, is in fact part of a very clear path that began with the quantification of greenhouse gas emissions related to the 2021 financial year and that will lead HAS Healthcare Advanced Synthesis to reduce all possible emissions by offsetting only the inevitable ones.
This important goal has been achieved as a result of the innovative and sustainable progress promoted by HAS Healthcare Advanced Synthesis over the last ten years, characterized by the desire to decarbonize its energy system and its production processes. Among the most important projects which have allowed HAS Healthcare Advanced Synthesis to reduce its carbon footprint over the years, is the connection, in 2017, to the district heating system plant in Biasca. This has made it possible to reduce CO2e emissions related to the use of fossil fuels (diesel) by over 90% through the use of woody biomass energy.
HAS Healthcare Advanced Synthesis: analysis of the CO2 emissions in 2021 and achievement of carbon neutrality
HAS Healthcare Advanced Synthesis first calculated its CO2 emissions in line with the methodology proposed by the GHG Protocol and ISO 14064-1. The reporting perimeter takes into account the majority of the company’s Scope 1, 2 and 3* emissions for the year 2021. The details relating to the calculation and reporting of emissions are available in the 2021 HAS Healthcare Advanced Synthesis “Advancing Together” Sustainability Report, available at the following link.
Subsequently, carbon neutrality was achieved by offsetting CO2 emissions for 2021 through the purchase of Gold Standard certified CO2 credits, one of the most accredited protocols globally for the development, certification and commercialization of carbon credits. Gold Standard certificates purchased by HAS Healthcare Advanced Synthesis support two high-quality projects, with the aim of providing clean water and cooking stoves to communities in Rwanda.
* The GHG Protocol Corporate Standard classifies a company’s greenhouse gas emissions into three “scopes”:
Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from purchased power generation. Scope 3 emissions are all indirect (not included in Scope 2) emissions that occur in the reporting company’s value chain, including upstream and downstream emissions.
Dr. Waldo Mossi, PhD, CEO, HAS Healthcare Advanced Synthesis, commented:
“Important investments in innovative technologies and plants that allow us to reduce the impact of our production activities on the environment, are always at the center of our attention. Today, I am proud to announce that our efforts to achieve sustainable growth have enabled HAS Healthcare Advanced Synthesis to achieve carbon neutrality in the year 2021. This is a concrete and tangible sign of our commitment to sustainable progress that respects the precious environment that we must safeguard”.
HAS Healthcare Advanced Synthesis is a CDMO that offers a full range of customized services from laboratory development to manufacturing. HAS Healthcare Advanced Synthesis develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, high-activity active pharmaceutical ingredients (HPAPIs) and anticancer compounds.
The production facility is located in Biasca, Switzerland, and was founded in 1984. The site is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. The production scale ranges from a few hundred grams to tens of kilograms for highly active ingredients (HPAPI) and anticancer and from kilograms to tens of tons for standard active ingredients (APIs); the plants are completely dedicated to cGMP production.
Contact Press Office
HAS Healthcare Advanced Synthesis
Tel: +41 (0) 91 873 94 00